Suche
Mein Konto
Vertex Pharmaceuticals acquires Alpine Immune Sciences merged with the pharmaceutical company
Learn how Vertex's acquisition of Alpine raises millions and its impact on stocks. All about the deal here! #Pharmaceutical industry #Stock market #Takeover #AlpineVertex
Vertex Pharmaceuticals acquires Alpine Immune Sciences merged with the pharmaceutical company
Pharmaceutical company Vertex announced on Wednesday that it will acquire biotechnology company Alpine. The transaction between Vertex Pharmaceuticals and Alpine Immune Sciences is expected to close in the second quarter. The acquisition has a positive impact on the shares of both companies.
Vertex Pharmaceuticals intends to acquire Alpine for $65 per share in cash. This represents a total equity value of approximately $4.9 billion. The transaction is subject to certain conditions, including acceptance of the offer by Alpine shareholders and regulatory approvals.
Investors reacted mixed to the takeover announcement. Alpine shares rose 20.80 percent, while Vertex shares initially fell 1.71 percent. However, in the following trading days, the mood improved and both Vertex and Alpine shares recorded positive price developments.
Vertex's acquisition of Alpine marks a significant event for both companies. Vertex looks forward to working with the talented Alpine team to advance innovative treatments. Vertex and Alpine shareholders are eagerly following further developments following this transaction.